Recent developments in the epidemiology and management of tuberculosis - new solutions to old problems?

Infection and Drug Resistance

Volumn 5, Issue 1, 2012, Pages 1-8

  Thaiss, Wolfgang M ^a   Thaiss, Cornelius C ^b   Thaiss, Christoph A ^c  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Management; Multidrug resistance; Tuberculosis; Vaccine

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BCG VACCINE; BEDAQUILINE; CAPREOMYCIN; COTRIMOXAZOLE; DELAMANID; ETHAMBUTOL; ISONIAZID; LINEZOLID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; SUTEZOLID;

ANTIBIOTIC RESISTANCE; BACTERIUM DETECTION; BCG VACCINATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LUNG TUBERCULOSIS; MIXED INFECTION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; SCREENING TEST; SHORT COURSE THERAPY; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNSPECIFIED SIDE EFFECT;

EID: 84861371832     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/idr.s27604     Document Type: Review

References (60)

1. Moore JE, Kruijshaar ME, Ormerod LP, Drobniewski F, Abubakar I. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland,1995-2006. BMC Public Health. 2010;10:612.
2. World Health Organization (WHO). Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. Geneva: WHO; 2006. Available from: http://whqlibdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf. Accessed November 22, 2011.
3. WHO. WHO Policy on TB Infection Control in Health-Care Facilities, Congregate Settings and Households. Geneva: WHO; 2009. Available from: http://whqlibdoc.who.int/publications/2009/9789241598323_eng.pdf. Accessed Oct 2011.
4. WHO. WHO Revised TB Reporting and Recording Registers. Geneva: WHO; 2006. Available from: http://whqlibdoc.who.int/hq/2006/WHO_HTM_TB_2006.373_eng.pdf. Accessed Oct 2011.
5. WHO. WHO Three I's meeting. Report of a Joint WHO HIV/AIDS and TB Department Meeting, 2008. Geneva: WHO; 2008. Available from: http://www.who.int/hiv/pub/meetingreports/WHO_3Is_meeting_report.pdf. Accessed Oct 2011.
6. WHO. WHO Report 2011: Global Tuberculosis Control. Available from: http://www.who.int/tb/publications/global_report/en/index.html. Accessed Oct 2011.
7. European Centre for Disease Prevention and Control and WHO. Surveillance Report: Tuberculosis Surveillance in Europe 2008. Stockholm: European Centre for Disease Prevention and Control; 2010. Available from: http://www.euro.who.int/_data/assets/pdf_file/0007/78856/E93600.pdf. Accessed Nov 2011.
8. Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011;378(9785):57-72.
9. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010;375(9728):1830-1843.
10. Shah NS, Wright A, Bai G-H, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerging Infect Dis. 2007;13(3): 380-387.
11. Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis - critical steps for prevention and control. N Engl J Med. 2010;363(11): 1050-1058.
12. Prasad R. Multidrug and extensively drug-resistant TB (M/XDR-TB): problems and solutions. Indian J Tuberc. 2010;57(4):180-191.
13. Lönnroth K, Castro KG, Chakaya JM,et al. Tuberculosis control and elimination 2010-2050: cure, care, and social development. Lancet. 2010;375(9728):1814-1829.
14. Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch Intern Med. 2007;167(4):335-342.
15. Stevenson CR, Forouhi NG, Roglic G, et al. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health. 2007;7:234.
16. Wilkinson RJ, Llewelyn M, Toossi Z, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet. 2000;355(9204):618-621.
17. Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol. 2007;179(4):2060-2063.
18. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8(10):601-611.
19. Nienhaus A, Schablon A, Torres Costa J, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res. 2011;11:247.
20. WHO. Treatment of Tuberculosis: Guidelines. 4th edn. Geneva: WHO; 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf. Accessed Nov 2011.
21. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(9):570-581.
22. WHO. Policy Framework for Implementing New Tuberculosis Diagnostics. Geneva: WHO; 2011. Available from: http://www.who.int/tb/laboratory/whopolicyframework_rev_june2011.pdf. Accessed Oct 2011.
23. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med. 1999;159(1): 15-21.
24. Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest. 2007;131(6):1898-1906.
25. Diel R, Goletti D, Ferrara G, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J. 2011;37(1):88-99.
26. WHO. The STOP TB Strategy. Geneva: WHO; 2006. Available from: http://www.stoptb.org/assets/documents/resources/publications/plan_strategy/The_Stop_TB_Strategy_Final.pdf. Accessed Nov 2011.
27. Pinto L, Menzies D. Treatment of drug-resistant tuberculosis. Infect Drug Resist. 2011;4:129-135.
28. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(3):153-161.
29. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinial management of XDR-TB: a systematic review by TBNET. Eur Respir J. 2009;33(4):871-881.
30. Nam H-S, Koh W-J, Kwon OJ, Cho S-N, Shim TS. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int J Antimicrob Agents. 2009;33(1):92-93.
31. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2005;191(2):150-158.
32. Lawn SD, Myer L, Edwards D, Bekker L-G, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009;23(13): 1717-1725.
33. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther. 2009;14(8):1039-1043.
34. WHO. Guidelines on Co-Trimoxazole Prophylaxis for HIV-related Infections among Children, Adolescents and Adults: Recommendations for a Public Health Approach. Geneva: WHO; 2006. Available from: http://www.who.int/hiv/pub/guidelines/ctxguidelines.pdf. Accessed Nov 2011.
35. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS. 2005;19(18):2109-2116.
36. Lawn SD, Myer L, Bekker L-G, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20(12):1605-1612.
37. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011; 365(16):1492-1501.
38. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother. 2006;57(2):167-170.
39. Aït-Khaled N, Alarcon E, Bissell K, et al. Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int J Tuberc Lung Dis. 2009;13(8):927-935.
40. Connell DW, Berry M, Cooke G, Kon OM. Update on tuberculosis: TB in the early 21st century. Eur Respir Rev. 2011;20(120):71-84.
41. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet. 2010;375(9729):1920-1937.
42. Sala C, Hartkoorn RC. Tuberculosis drugs: new candidates and how to find more. Future Microbiol. 2011;6(6):617-633.
43. Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis. 2011;11(8):633-640.
44. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010; 375(9731):2100-2109.
45. Marais BJ, Rabie H, Cotton MF. TB and HIV in children - advances in prevention and management. Paediatr Respir Rev. 2011;12(1): 39-45.
46. Zhang T, Li S-Y, Williams KN, Andries K, Nuermberger EL. Short-course chemotherapy with TMC-207 and rifapentine in a murine model of latent tuberculosis infection. Am J Resp Crit Care Med. Epub June 9, 2011.
47. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23): 2397-2405.
48. Williams KN, Brickner SJ, Stover CK, et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med. 2009;180(4):371-376.
49. Onajole OK, Govender P, van Helden PD, et al. Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates. Eur J Med Chem. 2010;45(5):2075-2079.
50. Gothi D, Joshi JM. Resistant TB: newer drugs and community approach. Recent Pat Antiinfect Drug Discov. 2011;6(1):27-37.
51. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011;15(7):949-954.
52. Mukherjee T, Boshoff H. Nitroimidazoles for the treatment of TB: past, present and future. Future Med Chem. 2011;3(11):1427-1454.
53. Kaufmann SH, Hussey G, Lambert P-H. New vaccines for tuberculosis. Lancet. 2010;375(9731):2110-2119.
54. Kernodle DS. Decrease in the effectiveness of Bacille Calmette-Guérin vaccine against pulmonary tuberculosis: a consequence of increased immune suppression by microbial antioxidants, not overattenuation. Clin Infect Dis. 2010;51(2):177-184.
55. Rowland R, McShane H. Tuberculosis vaccines in clinical trials. Expert Rev Vaccines. 2011;10(5):645-658.
56. Thaiss CA, Kaufmann SH. Toward novel vaccines against tuberculosis: current hopes and obstacles. Yale J Biol Med. 2010;83(4): 209-215.
57. Desel C, Dorhoi A, Bandermann S, Grode L, Eisele B, Kaufmann SHE. Recombinant BCG {Delta}ureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis. 2011;204(10):1573-1584.
58. Kaufmann SH. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity. 2010;33(4):567-577.
59. Kaufmann SH. Novel tuberculosis vaccination strategies based on understanding the immune response. J Intern Med. 2010;267(4): 337-353.
60. Parida SK, Kaufmann SH. The quest for biomarkers in tuberculosis. Drug Discov Today. 2010;15(3-4):148-157.